Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Core Insights - Shuttle Pharmaceuticals Holdings, Inc. has appointed Christopher Cooper as interim Co-Chief Executive Officer to enhance capital markets and business capabilities [1][2] - Dr. Anatoly Dritschilo will continue as Co-CEO, focusing on scientific and clinical trial activities [1][2] - The dual CEO structure aims to improve decision-making, support fundraising, and accelerate key milestones [2] Company Overview - Shuttle Pharmaceuticals, founded in 2012, is a specialty pharmaceutical company focused on improving outcomes for cancer patients undergoing radiation therapy [3] - The company's mission is to develop therapies that maximize the effectiveness of radiation therapy while minimizing side effects [3] - Shuttle Pharma aims to increase cancer cure rates, prolong survival, and improve quality of life through the development of radiation sensitizers [3] Leadership Background - Christopher Cooper has over 27 years of experience in management and finance across various industries, including telecommunications and oil and gas [2] - He has held significant positions such as President and CEO of First Towers & Fiber Corp. and Aroway Energy, Inc. [2] - Cooper has a proven track record in overseeing operations, financial reporting, and raising over $100 million in debt and equity for clients [2]